Xenolith Medical

Company Overview

Snapshot

Founded in July 2010 by Shaul Shohat and Ido Kilemnik, Xenolith Medical operates with 1–10 employees. The company has secured funding across one disclosed round from two investors, including Xenia Venture Capital. Xenolith Medical ceased operations in February 2018.

Business overview

Xenolith Medical specializes in adapting angioplasty retention and navigation technologies for endourology, focusing on preventing stone fragment migration during ureteroscopic lithotripsy. Its core product, XenX, utilizes a self-expandable braided mesh with a high expansion ratio, allowing for slender insertion and expansion within the ureter. The company serves the healthcare industry, particularly doctors and hospitals, in the medical devices and medical treatment & therapeutics sectors across markets like Europe and the United States.

Company Intelligence Q&A

What is Xenolith Medical's primary product?

Xenolith Medical's primary product is XenX, a device designed to prevent the migration of stone fragments during ureteroscopic lithotripsy procedures.

When was Xenolith Medical founded?

Xenolith Medical was founded in July 2010 by Shaul Shohat and Ido Kilemnik.

What is the status of Xenolith Medical?

Xenolith Medical ceased to operate in February 2018 and is currently listed as Non-Active.

Which investors participated in Xenolith Medical's funding round?

In January 2011, Xenolith Medical received funding from Virginia Life Sciences Investments (VLSI) and Xenia Venture Capital.

What technology does Xenolith Medical utilize in its products?

Xenolith Medical utilizes a mechanical structure implemented as a self-expandable braided mesh with an ultra-high expansion ratio, enabling insertion as a slender wire and expansion up to 12 millimeters in the ureter.